Diabetes Roundup: Rise in Cannabis Use Among Adults, GLP-1 Trends, and More

More Adults with Diabetes are Using Cannabis Despite Potential Risks

Diabetes Roundup: Rise in Cannabis Use Among Adults, GLP-1 Trends, and More / Minerva Studios - stock.adobe.com

There has been a significant increase in the use of cannabis among adults with diabetes in the United States despite the drug’s unclear impacts on health outcomes, according to recent data published in the journal Diabetes Care. The authors said that the findings support the use of screening and education about potential risks.

Children with T1D at Increased Risk of Psychiatric Disorders Later in Life

A diagnosis with type 1 diabetes (T1D) in childhood is associated with an increased risk of many different psychiatric disorders later in life, according to new data published in the journal Nature Mental Health. The authors said the findings emphasize the need to monitor and address the mental health needs of children with diabetes.

Novo Nordisk Once-Weekly Insulin Faces Approval Setback With CRL

The FDA issued a Complete Response Letter (CRL) to Novo Nordisk for the company’s once-weekly basal insulin icodec for the treatment of diabetes. The agency said it requires additional details on the manufacturing process as well as the drug’s indication for type 1 diabetes (T1D) before it can complete its review of a Biologics License Application. Novo Nordisk said it will not be able to provide this information until next year.

Head to Head Comparison of GLP-1 RAs for Weight Loss Tips Scales in Tirzepatide’s Favor

Tirzepatide is associated with significantly more weight loss than semaglutide in adults with overweight or obesity, according to results of a real-world study published in JAMA Internal Medicine. Investigators set out to compare both on-treatment weight loss and gastrointestinal adverse events in a cohort of adults who received either drug between May 2022 and September 2023.

SGLT2i, GLP-1RA Combination Therapy Offers Robust Protection Against Cardiovascular, Kidney Disease

Combining sodium glucose co-transporter 2 inhibitors (SGLT2is) with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer additional protection against cardiovascular and kidney disease in patients with type 2 diabetes (T2D), according to the results of a new meta-analysis published in The Lancet Diabetes & Endocrinology and presented at the 61st European Renal Association Congress in Stockholm, Sweden.

Slideshow: Impact of Nutrition, Social Support, and More in Managing T2D

Managing type 2 diabetes (T2D) involves a multi-pronged approach. It relies on lifestyle changes, medications, blood sugar monitoring, and ongoing education. However, research in T2D management is ever-changing; by continuously exploring and refining these pillars of management, health care professionals can optimize health outcomes for patients with the condition.

Mediterranean, DASH Diets May Lower Risk of Cardiovascular Disease in Patients with T1D

Patients with type 1 diabetes who have higher adherence to guidelines from the Mediterranean or dietary approaches to stop hypertension (DASH) diets may have a lower risk of cardiovascular disease, according to new data. The study builds on earlier work from the researchers and was presented at Nutrition 2024, the American Society for Nutrition’s annual meeting held June 29 to July 2 in Chicago, Illinois.

GLP-1 Use and Risk of Cardiovascular Events in Different Patient Populations

Glucagon-like peptide-1 receptor agonists (GLP-1s) have proven to be effective at improving glycemic control in patients with type 2 diabetes and reducing body weight in individuals with obesity or overweight. However, more recent research has also shown that this class of drugs can improve cardiovascular outcomes, including reducing the rates of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.

Examining GLP-1 Trends in T2D, Risk of Obesity-Related Malignancies

Glucagon-like peptide-1 receptor agonists (GLP-1s) have gained widespread attention over the last several years. The class of drugs, which includes semaglutide and tirzepatide, are used to treat type 2 diabetes and obesity or overweight. Research has shown that GLP-1s are effective at improving glycemic control, reducing body weight, and lowering the risk of major adverse cardiovascular events.

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.